Rezolute (RZLT) to Release Earnings on Wednesday

Rezolute (NASDAQ:RZLT) will likely be posting its Q3 2025 quarterly earnings results before the market opens on Wednesday, May 21st. Analysts expect Rezolute to post earnings of ($0.22) per share for the quarter.

Rezolute (NASDAQ:RZLT) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.05). On average, analysts expect Rezolute to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Rezolute Stock Performance

RZLT opened at $3.67 on Wednesday. The company’s 50 day simple moving average is $3.24 and its 200 day simple moving average is $4.34. Rezolute has a 1 year low of $2.22 and a 1 year high of $6.19. The stock has a market capitalization of $222.16 million, a PE ratio of -3.01 and a beta of 1.01.

Insider Buying and Selling at Rezolute

In other news, Director Wladimir Hogenhuis bought 10,000 shares of Rezolute stock in a transaction dated Tuesday, February 18th. The shares were acquired at an average cost of $4.70 per share, with a total value of $47,000.00. Following the completion of the transaction, the director now owns 77,267 shares in the company, valued at approximately $363,154.90. This trade represents a 14.87% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Nevan C. Elam bought 12,302 shares of Rezolute stock in a transaction dated Thursday, March 27th. The shares were purchased at an average cost of $2.85 per share, for a total transaction of $35,060.70. Following the completion of the transaction, the chief executive officer now owns 224,119 shares of the company’s stock, valued at approximately $638,739.15. This represents a 5.81% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 39,060 shares of company stock valued at $130,694 over the last ninety days. Corporate insiders own 18.39% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on RZLT shares. JMP Securities raised their target price on shares of Rezolute from $8.00 to $9.00 and gave the stock a “market outperform” rating in a research report on Thursday, February 13th. Craig Hallum raised shares of Rezolute to a “strong-buy” rating in a research report on Tuesday, February 4th. HC Wainwright reissued a “buy” rating and issued a $14.00 target price on shares of Rezolute in a research report on Monday, April 28th. Finally, Guggenheim reissued a “buy” rating on shares of Rezolute in a research report on Monday, February 10th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $26.43.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.